Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline results in a Phase 3b study (NCT06973577) evaluating ...

Axsome Therapeutics AXSM announced that it has dosed the first patient in the phase III FOCUS-2 study evaluating solriamfetol ...

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHDNEW YORK, July 07, 2026 (GLOBE NEWSWIRE) ...

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm ...

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Investors are betting that a deeper understanding of the brain will allow BCI systems to address the significant unmet need affecting millions of people with neurological disorders. They are also ...

Age and sex may influence the distinct inflammatory cytokine perturbations observed in autism spectrum disorder and ADHD.

A school project prompted 17-year-old Edward Kang to develop an AI tool that may lead to earlier diagnoses of the disorders.

Among the many myths and misunderstandings of Attention-Deficit/Hyperactivity Disorder is that exceptionally smart people can’t have ADHD (or, conversely, that ADHD ...

President Donald Trump’s approval rating is unchanged from last month in the latest poll taken as the U.S. reached an agreement with Iran to end the war—though the majority of Americans still said U.S ...

Actor Shahid Kapoor has reacted to his new release Cocktail 2 being given an A certificate by the Central Board of Film Certification (CBFC). The Homi Adajania directorial, featuring actors Rashmika ...